Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma

BACKGROUND: Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS (⩾30 months) were investigated in sunitinib-treated patients with metastatic renal cell carcinoma (RCC). METHODS: Data were pooled from 1059 patients in six trials. Baseline variables, includi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Motzer, R J, Escudier, B, Bukowski, R, Rini, B I, Hutson, T E, Barrios, C H, Lin, X, Fly, K, Matczak, E, Gore, M E
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2013
Aiheet:
Clinical Study
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3694236/
https://ncbi.nlm.nih.gov/pubmed/23695024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.236
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia